Theratechnologies to Present at the Cantor Fitzgerald Global Healthcare Conference 2023
MONTREAL, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Mr. Paul Lévesque, President and Chief Executive Officer, will participate in a panel presentation at the Cantor Fitzgerald Global Healthcare Conference 2023 being held September 26-28 in New York City.
Presentation Details
Date:
Wednesday, September 27, 2023
Time:
8:00 - 8:30 AM EDT in Track 2
Location:
Intercontinental Barclay New York Hotel
Mr. Lévesque and Mr. Philippe Dubuc, Senior Vice President and Chief Financial Officer, will also be available for 1x1 investor meetings.
About Theratechnologies
Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Further information about Theratechnologies is available on the Company's website at www.theratech.com, on SEDAR at www.sedarplus.ca and on EDGAR at www.sec.gov. Follow Theratechnologies on Linkedin and Twitter.
Contacts:
Investor Inquiries: Philippe Dubuc Senior Vice President and Chief Financial Officer [email protected] 438-315-6608
Chrysalis BioTherapeutics today announced it was selected to participate in the 2024 Respiratory Innovation Summit (RIS) at the American Thoracic Society Meeting in San Diego.
The Respiratory Innovation Summit (RIS) has been established by the...
Ansa Biotechnologies, Inc., the trusted partner for complex DNA synthesis, today announced that it is expanding its early access program for its complex DNA synthesis services. More customers around the world will now be able to take advantage of the...
Boundless Bio , a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Boundless Bio Chief...
Lineage Cell Therapeutics, Inc. , a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that 24 month visual acuity results from patients enrolled in a Phase 1/2a clinical study...
Phonak, a leading global provider of life-changing hearing solutions, today announces an FDA cleared self-replacement option for Phonak Lyric, the world's only 100% invisible hearing aid? that provides 24/7 hassle-free hearing? with proven tinnitus...
Takara Bio USA, Inc., a wholly owned subsidiary of Takara Bio Inc., today announced the launch of the Lenti-Xtm Transduction Sponge, a first-to-market dissolvable microfluidic transduction enhancer that innovates in vitro lentivirus-mediated gene...
